



BRAWN



EE99B

CIN NO.: L74899DL1985PLC022468

29th May 2023

The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207

Scrip ID: BRAWN

Sub: Outcome of Board Meeting and Submission of Audited Financial Results for the quarter and year ended 31.03.2023.

Dear Sir/ Ma'am,

Pursuant to the Regulation 30 and 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and any other applicable provisions, if any, we wish to inform you that a meeting of the Board of Directors of the Company was held today i.e. 29th May, 2023, have inter alia considered, approved and taken on record the Standalone Financial Results of Brawn Biotech Limited for the fourth quarter and financial year ended March 31st 2023, which was recommended by the Audit Committee at their meeting held on 29th May, 2023.

Further, pursuant to provisions of Regulation 33 of SEBI Listing Regulations, please find enclosed herewith Standalone Audited Financial Results, along with Auditor's report and declaration on unmodified Audit Report.

We wish to further inform you that the meeting of the Board of directors commenced at 04:00 PM and concluded at 04:40 PM.

This is for your kind information and record.

FOR BRAWN BIOTECH LIMITED

Priyanka Sharma
Company Secretary and Compliance Officer



BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129515331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222452
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life



CIN NO.: L74899DL1985PLC022468

**BRAWN**

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2023

Rs. In Lacs

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-23	31-Dec-22	31-Mar-22	31-Mar-23	31-Mar-22
		Un-audited	Un-audited	Un-audited	Audited	Audited
1	Revenue from operations					
	Revenue from operations	475.26	630.89	288.71	2,223.06	862.05
	Other Income	0.37	0.23	(8.83)	0.92	0.37
	Total Revenue	475.63	631.13	279.88	2,223.99	862.42
2	Expenses					
a	Cost of material consumed	(7.75)	2.31	-	-	-
b	Purchase of stock-in-trade	322.85	638.43	378.50	1,924.47	1,105.35
c	Change in inventories of finished goods, work in progress and stock in trade	76.88	(88.08)	(208.33)	(6.77)	(446.68)
d	Employee Benefit expenses	38.21	32.56	45.03	139.92	180.44
e	Depreciation and amortisation expenses	3.54	2.61	2.00	10.91	5.33
f	Finance Cost	0.38	0.03	0.51	0.82	6.25
g	Other expenses	58.12	46.99	46.51	195.79	223.51
	Total Expenses	492.22	634.85	264.22	2,265.14	1,074.20
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	(16.59)	(3.72)	15.66	(41.15)	(211.78)
4	Other Income	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	(16.59)	(3.72)	15.66	(41.15)	(211.78)
6	Exceptional Items	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	(16.59)	(3.72)	15.66	(41.15)	(211.78)
8	Tax Expenses	44.21	-	(47.34)	45.66	(47.34)
9	Profit (Loss) for the period from continuing operations (7-8)	(60.80)	(3.72)	63.00	(86.81)	(164.44)
10	Profit/(loss) from discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	(60.80)	(3.72)	63.00	(86.81)	(164.44)
14	Other Comprehensive Income	(0.23)	-1.77	1.75	(4.30)	6.96
	Total Comprehensive Income	(61.03)	(5.49)	64.75	(91.11)	(157.48)
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital					
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve					
17	Earnings per share					
i	Basic earnings per share	(2.03)	(0.18)	2.16	(3.04)	(5.25)
ii	Diluted earnings per share	(2.03)	(0.18)	2.16	(3.04)	(5.25)

NOTES:-

- Results for the quarter and year ended on 31st March, 2023 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 29th May, 2023.
- The Statutory Auditors carried out the audit for year ended 31st March, 2023. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone audited Financial Results for the quarter and year ended ended on 31.03-2023 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Figures for the quarter ended 31st March 2023 are the differences between the figures for the year ended 31st March 2023 and Nine month ended 31st December 2022.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Date: 29-05-2023
Place: Delhi

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life



Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015, as amended

**To
The Board of Directors of
Brawn Biotech Limited**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Brawn Biotech Limited (the "Company") for the quarter ended March 31, 2023 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

is presented in accordance with requirements of the Listing Regulations in this regard; and gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2023 and for the year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with



the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional Skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the statement that, individually or in aggregate makes it probable that the economic decisions of a reasonably knowledgeable user of the statement may be influenced, We consider quantitative materiality and qualitative factors in (i) Planning the scope of our audit, work and in evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the statements


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N


Rajeev Jain
(Partner)

Membership No.: 099767
UDIN: 23099767BGSJHX8837



Place: Delhi
Date: 29-05-2023



BRAWN



91609

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Rs. in Lacs		
Statement of Assets and Liabilities as on 31st March 2023		
Particulars	31-Mar-23 Audited	31-Mar-22 Audited
ASSETS		
(1) Non-Current Assets		
Property, Plant, Equipment & Intangible Assets	37.25	38.59
Financial Assets		
-Investment		
- Trade Receivable	59.94	58.80
-Loan		
Deferred Tax Asset (Net)	15.94	62.41
Total Non-Current Assets	113.12	159.80
(2) Current Assets		
Inventories	479.13	472.36
Financial Assets		
- Trade Receivables	531.54	280.98
- Cash and cash equivalents	43.88	22.46
- Loan	1.62	1.27
- Other Financial Assets	112.65	112.65
Current Tax Assets (Net)		69.67
Other Current Assets	171.11	259.27
Total Current Assets	1,339.93	1,218.66
TOTAL ASSETS	1,453.05	1,378.46
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	300.03	300.03
Other Equity	330.90	422.01
TOTAL EQUITY	630.93	722.04
LIABILITIES		
(1) Non-current Liabilities		
Financial Liabilities		
- Trade Payable	7.79	16.75
- Other Financial Liabilities		
Provisions	9.67	7.57
Deferred Tax liabilities (Net)		
Total Non-Current Liabilities	17.46	24.32
(2) Current Liabilities		
Financial Liabilities		
- Trade Payables	646.90	405.19
- Other Financial Liabilities	42.44	48.34
Other current liabilities	107.79	100.32
Provisions	7.53	8.57
Current tax liabilities		69.67
Total Current Liabilities	804.66	632.10
TOTAL EQUITY AND LIABILITIES	1,453.05	1,378.46

For and on behalf of Board
For Brawn Biotech Limited


Brij Raj Gupta
Director
DIN NO. 00974969
Place : New Delhi
Date: 29-05-2023

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana , INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life

**BRAWN**

Brawn Biotech Limited
Cash Flow Statement for the year ended 31st March 2023
CIN NO: L74899DL1985PLC022468



CIN NO.: L74899DL1985PLC022468

9BATE

Rs. in Lacs

Particulars	For the year ended		For the year ended	
	31.03.2023		31.03.2022	
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		(41.15)		(211.78)
Adjustments for:				
Profit of sale of Investment (Shares)				
Depreciation and amortisation	10.91		5.33	
Re-measurement losses on defined benefit plans	(4.30)		6.96	
Finance costs	0.82	7.43	6.25	18.54
Operating profit / (loss) before working capital changes		(33.72)		(193.24)
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	(6.77)		(446.68)	
Trade receivables	(250.56)		646.84	
Long Term - Trade receivables	(1.14)		26.75	
Short-term loans and advances	157.48		(163.46)	
Long-term loans and advances				
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	241.71		139.28	
Long Term - Trade payables	(8.95)		11.79	
Borrowings				
Other current liabilities	7.47		43.69	
Other financial liabilities	(5.90)		(40.51)	
Current tax liabilities	(69.67)			
Long-term provisions	2.09		(5.05)	
Short-term provisions	(1.04)	64.72	(0.63)	212.02
Cash flow from extraordinary items				
Cash generated from operations		31.00		18.78
Net income tax (paid) / refunds & Dividend		0.80		
Net cash flow from / (used in) operating activities (A)		31.80		18.78
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advances	(9.56)		(29.70)	
Cash flow from extraordinary items				(29.70)
Net cash flow from / (used in) Investing activities (B)		(9.56)		(29.70)
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Proceeds from other short-term borrowings				
Finance cost	(0.82)		(6.25)	(6.25)
Cash flow from extraordinary items				
Net cash flow from / (used in) financing activities (C)		(0.82)		(6.25)
Net Increase / (decrease) In Cash and cash equivalents (A+B+C)		21.42		(17.16)
Cash and cash equivalents at the beginning of the year		22.46		39.63
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents				
Cash and cash equivalents at the end of the year		43.88		22.46
Reconciliation of Cash and cash equivalents with the Balance Sheet:				
Cash and cash equivalents as per Balance Sheet (Refer Note- B)		43.88		22.46
Less: Bank balances not considered as Cash and cash equivalents				
Net Cash and cash equivalents		43.88		22.46
Add: Current investments considered as part of Cash and cash equivalents				
Cash and cash equivalents at the end of the year *		43.88		22.46
* Comprises:				
(a) Cash on hand		8.60		5.81
(b) Cheques, drafts on hand				
(c) Balances with banks				
(i) In current accounts		35.28		16.65

Notes:

(i) The Cash Flow Statement reflects the combined cash flows pertaining to continuing and discounting operations.

(ii) These earmarked account balances with banks can be utilised only for the specific identified purposes.

Significant Accounting Policies & Notes on Financial Statements

For and on behalf of Board

For Brawn Biotech Limited

Brij Raj Gupta

Director

DIN NO. 00974969

Place : New Delhi

Date: 29-05-2023

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

... for better life